Illumina Inc.

Illumina Inc.

Prezzo: 160.97

Società e modello di business

Illumina Inc. specializes in genomic sequencing and analysis, providing tools and services for genetic research and diagnostics. Its core products include sequencing systems, reagents, and software for data analysis. Major business segments encompass research and clinical applications, with primary revenue sources derived from sales of sequencing instruments and consumables, as well as service agreements. The company serves a diverse clientele, including academic institutions, pharmaceutical companies, and healthcare providers.

Profilo di investimento

The investment profile of Illumina Inc. is more aligned with growth investors, given its focus on innovation in genomic technology and potential for market expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends. The company's recent performance indicates moderate volatility, suggesting a balanced approach may be prudent for investors.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $
5.54 OK
Ricavi QoQ — crescita dei ricavi trimestre su trimestre
-5.9%
Sorpresa EPS
9.5% meglio del previsto
Volatilità 20g
2.4% stabile
Dati FMP / FinFeed aggiornati: 2026-06-13

Impatto della previsione

positivo
Target alzato · Guggenheim · valido fino a 2026-07-01 · aggiornato 2026-06-13
Target +11.8% raggiungimento target 89.4%
Reazione D5 -0.47% · D10 +4.73% fiducia mercato
Impatto Potenziale +3 · Rischio -1 fino a 30 giorni o finché il target non viene raggiunto
Racc.: Mantieni Potenziale: 62 Rischio: 65 Aggiornato: 2026-06-13 02:40
Come funziona la raccomandazione
Perché l'AI la pensa così:
Weak fundamentals and high risk; cautious approach advised.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell
Cambiamenti di raccomandazione AI
Data Prima Dopo Motivo
2026-06-05 02:40 Compra Mantieni Weak fundamentals with mixed momentum signals.
2026-05-28 02:47 Mantieni Compra Strong momentum, but revenue decline raises concerns.
2026-05-08 15:03 Mantieni Mixed momentum; fundamentals show some weakness.
Previsioni analisti
Data Analista Action Target Prezzo allora
2026-06-01 11:27 Guggenheim Target alzato 170 → 180 162.96
2026-05-14 20:23 RBC Capital Aggiorna — → 170 143.24
2026-05-14 09:05 Daiwa Rating migliorato — → 155 145

Ancora nulla